BPI antibody

Catalog No. ABIN2191910

The Mouse Monoclonal anti-BPI antibody has been validated for IA. It is suitable to detect BPI in samples from Human.

Quick Overview for BPI antibody (ABIN2191910)

Target: BPI (Bactericidal/Permeability Increasing Protein (BPI))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This BPI antibody is un-conjugated

Application: Immunoassay (IA)

Clone: 3F9

Product Details anti-BPI Antibody

Sterility: 0.2 μm filtered

Application Details

Application Notes: The monoclonal antibody 3F9 can be used for immuno assays both as coating and as detector.

Restrictions: For Research Use only

Handling

Buffer: PBS, containing 0.1 % bovine serum albumin and 0.02 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.

Expiry Date: 12 months

Target Details for BPI

Target: BPI (Bactericidal/Permeability Increasing Protein (BPI))

Alternative Name: Bactericidal Permeability Increasing Protein

Background: The monoclonal antibody 3F9 reacts specifically with full length human natural and recombinant Bactericidal Permeability Increasing protein (BPI). The antimicrobial protein BPI is a 55 kDa protein found in the primary (azurophilic) granules of human neutrophils and has also been detected on surface of neutrophils, small intestinal and oral epithelial cells. BPI is a bactericidal compound that is present in polymorphonuclear cells (PMN) and in lower levels in the specific granules of eosinophils. BPI possesses high affinity toward the lipid A region of lipopolysaccharides (LPS) that comprise the outer leaflet of the gram-negative bacterial outer membrane. Binding of BPI to the lipid A moiety of LPS exerts multiple anti-infective activities against gram-negative bacteria: 1) cytotoxicity via sequential damage to bacterial outer and inner lipid membranes, 2) neutralization of gram-negative bacterial LPS, 3) opsonization of bacteria to enhance phagocytosis by neutrophils. Airway epithelial cells constitutively express the BPI gene and produce the BPI protein and, therefore, BPI may be a critical determinant in the development of LPS-triggered airways disease. Inflammation induced by LPS possibly contributes to the development of rapid airflow decline, a serious and often fatal complication of hematopoietic cell transplantation. Furthermore, a 21 kDa bioactive recombinant fragment of BPI, rBPI21, was shown to confer a survival advantage against invasive pneumococcal disease by binding to the gram-positive bacterial pathogen, pneumolysin. The monoclonal antibody 3F9 recognizes only free BPI and does not interact with BPI that has formed a complex with LPS.